INMUNE BIO INC (INMB) Fundamental Analysis & Valuation

NASDAQ:INMB • US45782T1051

Current stock price

1.26 USD
-0.03 (-2.33%)
Last:

This INMB fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. INMB Profitability Analysis

1.1 Basic Checks

  • INMB had negative earnings in the past year.
  • INMB had a negative operating cash flow in the past year.
  • INMB had negative earnings in each of the past 5 years.
  • In the past 5 years INMB always reported negative operating cash flow.
INMB Yearly Net Income VS EBIT VS OCF VS FCFINMB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M -40M

1.2 Ratios

  • INMB's Return On Assets of -141.98% is on the low side compared to the rest of the industry. INMB is outperformed by 82.79% of its industry peers.
  • INMB has a worse Return On Equity (-195.26%) than 68.67% of its industry peers.
Industry RankSector Rank
ROA -141.98%
ROE -195.26%
ROIC N/A
ROA(3y)-100.33%
ROA(5y)-72.95%
ROE(3y)-135.02%
ROE(5y)-97.66%
ROIC(3y)N/A
ROIC(5y)N/A
INMB Yearly ROA, ROE, ROICINMB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100 -100

1.3 Margins

  • INMB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
INMB Yearly Profit, Operating, Gross MarginsINMB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100K -200K -300K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. INMB Health Analysis

2.1 Basic Checks

  • INMB does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, INMB has more shares outstanding
  • INMB has more shares outstanding than it did 5 years ago.
  • INMB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
INMB Yearly Shares OutstandingINMB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M 25M
INMB Yearly Total Debt VS Total AssetsINMB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

2.2 Solvency

  • INMB has an Altman-Z score of -9.07. This is a bad value and indicates that INMB is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of -9.07, INMB is not doing good in the industry: 71.76% of the companies in the same industry are doing better.
  • There is no outstanding debt for INMB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -9.07
ROIC/WACCN/A
WACC9.21%
INMB Yearly LT Debt VS Equity VS FCFINMB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M -40M 60M 80M

2.3 Liquidity

  • INMB has a Current Ratio of 3.55. This indicates that INMB is financially healthy and has no problem in meeting its short term obligations.
  • INMB has a Current ratio (3.55) which is in line with its industry peers.
  • INMB has a Quick Ratio of 3.55. This indicates that INMB is financially healthy and has no problem in meeting its short term obligations.
  • INMB has a Quick ratio (3.55) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 3.55
Quick Ratio 3.55
INMB Yearly Current Assets VS Current LiabilitesINMB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. INMB Growth Analysis

3.1 Past

  • INMB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 9.00%, which is quite good.
  • Looking at the last year, INMB shows a very strong growth in Revenue. The Revenue has grown by 257.14%.
  • The Revenue has been growing by 37.97% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
Revenue 1Y (TTM)257.14%
Revenue growth 3Y-48.68%
Revenue growth 5Y37.97%
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 27.15% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, INMB will show a very strong growth in Revenue. The Revenue will grow by 388.13% on average per year.
EPS Next Y54.84%
EPS Next 2Y23.72%
EPS Next 3Y20.7%
EPS Next 5Y27.15%
Revenue Next Year-100%
Revenue Next 2Y908.75%
Revenue Next 3Y637.4%
Revenue Next 5Y388.13%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
INMB Yearly Revenue VS EstimatesINMB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M 400M
INMB Yearly EPS VS EstimatesINMB Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4 6

More info and screens

Find the best growth stocksShow best growing peers

1

4. INMB Valuation Analysis

4.1 Price/Earnings Ratio

  • INMB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year INMB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
INMB Price Earnings VS Forward Price EarningsINMB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INMB Per share dataINMB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

  • A more expensive valuation may be justified as INMB's earnings are expected to grow with 20.70% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.72%
EPS Next 3Y20.7%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. INMB Dividend Analysis

5.1 Amount

  • INMB does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

INMB Fundamentals: All Metrics, Ratios and Statistics

INMUNE BIO INC

NASDAQ:INMB (4/9/2026, 11:45:22 AM)

1.26

-0.03 (-2.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-30
Earnings (Next)05-06
Inst Owners18.02%
Inst Owner Change0%
Ins Owners17.01%
Ins Owner Change0%
Market Cap33.50M
Revenue(TTM)50.00K
Net Income(TTM)-45.93M
Analysts82
Price Target7.14 (466.67%)
Short Float %14.79%
Short Ratio7.22
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)26.09%
Min EPS beat(2)24.59%
Max EPS beat(2)27.6%
EPS beat(4)3
Avg EPS beat(4)-26.81%
Min EPS beat(4)-169.71%
Max EPS beat(4)27.6%
EPS beat(8)5
Avg EPS beat(8)-10.98%
EPS beat(12)6
Avg EPS beat(12)-147.12%
EPS beat(16)10
Avg EPS beat(16)-102.74%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)33.33%
PT rev (3m)33.33%
EPS NQ rev (1m)-6.95%
EPS NQ rev (3m)-19.38%
EPS NY rev (1m)0%
EPS NY rev (3m)0.99%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 670.07
P/FCF N/A
P/OCF N/A
P/B 1.42
P/tB 1.42
EV/EBITDA N/A
EPS(TTM)-1.92
EYN/A
EPS(NY)-0.87
Fwd EYN/A
FCF(TTM)-0.89
FCFYN/A
OCF(TTM)-0.85
OCFYN/A
SpS0
BVpS0.88
TBVpS0.88
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -141.98%
ROE -195.26%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-100.33%
ROA(5y)-72.95%
ROE(3y)-135.02%
ROE(5y)-97.66%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1240.48%
Cap/Sales 2084%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.55
Quick Ratio 3.55
Altman-Z -9.07
F-Score5
WACC9.21%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
EPS Next Y54.84%
EPS Next 2Y23.72%
EPS Next 3Y20.7%
EPS Next 5Y27.15%
Revenue 1Y (TTM)257.14%
Revenue growth 3Y-48.68%
Revenue growth 5Y37.97%
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y908.75%
Revenue Next 3Y637.4%
Revenue Next 5Y388.13%
EBIT growth 1Y27.12%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y29.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y32.31%
OCF growth 3YN/A
OCF growth 5YN/A

INMUNE BIO INC / INMB Fundamental Analysis FAQ

What is the ChartMill fundamental rating of INMUNE BIO INC (INMB) stock?

ChartMill assigns a fundamental rating of 4 / 10 to INMB.


What is the valuation status for INMB stock?

ChartMill assigns a valuation rating of 1 / 10 to INMUNE BIO INC (INMB). This can be considered as Overvalued.


Can you provide the profitability details for INMUNE BIO INC?

INMUNE BIO INC (INMB) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for INMB stock?

The Earnings per Share (EPS) of INMUNE BIO INC (INMB) is expected to grow by 54.84% in the next year.